

- 1 AbbVie. Data on File, ABVRRTI66053.
- 2 AbbVie. Data on File, ABVRRTI65458.
- 3 AbbVie. Data on File, ABVRRTI64730.
- 4 AbbVie. Data on File, ABVRRTI64466.
- 5 Kremer JM, Emery P, Camp HS, et al. A Phase 2b study of ABT-494, a selective JAK1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-TNF therapy. *Arthritis Rheumatol* 2016; (doi:10.1002/art.39801): July 7 [Epub ahead of print].
- 6 Genovese MC, Smolen JS, Weinblatt ME, et al. A randomized Phase 2b study of ABT-494, a selective JAK1 inhibitor in patients with rheumatoid arthritis and an inadequate response to methotrexate. *Arthritis Rheumatol* 2016;(doi: 10.1002/art.39808):July 7 [Epub ahead of print].
- 7 Voss, J, et al; Pharmacodynamics Of a Novel Jak1 Selective Inhibitor In Rat Arthritis and Anemia Models and In Healthy Human Subjects. [abstract]. *Arthritis Rheum* 2013;65 Suppl 10 :2374. DOI: 10.1002/art.2013.65.issue-s10
- 8 Pipeline – Our Science | AbbVie. AbbVie. 2017. Available at: <https://www.abbvie.com/our-science/pipeline.html>. Accessed on April 5, 2018.
- 9 A Study Comparing ABT494 to Placebo in Subjects With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone (SELECT-NEXT). *ClinicalTrials.gov*. 2018. Available at: <https://clinicaltrials.gov/ct2/show/NCT02675426>. Accessed on April 5, 2018.
- 10 A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (SELECT - PsA 1). *ClinicalTrials.gov*. 2018. Available at: <https://clinicaltrials.gov/ct2/show/NCT03104400>. Accessed on April 5, 2018.
- 11 A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy. *Clinicaltrials.gov*. 2018. Available at: <https://www.clinicaltrials.gov/ct2/show/NCT03345836>. Accessed April 5, 2018.
- 12 A Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects With Active Ankylosing Spondylitis (SELECT Axis 1). 2018. Available at: <https://clinicaltrials.gov/ct2/show/study/NCT03178487>. Accessed on April 5, 2018.
- 13 A Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis. *ClinicalTrials.gov*. 2018. Available at: <https://clinicaltrials.gov/ct2/show/NCT02819635>. Accessed on April 5, 2018.

- 14 A Study to Evaluate ABT-494 in Adult Subjects With Moderate to Severe Atopic Dermatitis. ClinicalTrials.gov. 2018. Available at: <https://clinicaltrials.gov/ct2/show/NCT02925117>. Accessed on April 5, 2018.
- 15 World Health Organization. The Global Burden of Disease, 2004 Update. Available at: http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf. Accessed on March 5, 2018.
- 16 Nagy G, van Vollenhoven RF. Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now? *Arthritis Res Ther* 2015; 17:181.
- 17 Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis* 2017. pii: annrheumdis-2016-210715. [Epub ahead of print]
- 18 Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Rheumatol* 2016;68(1):1-26.
- 19 Favalli EG., et al. Structural integrity versus radiographic progression in rheumatoid arthritis. *Rheumatoid & Musculoskeletal Diseases*. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632139/>. Accessed on April 5, 2018.
- 20 Kim SC. Risk of Venous Thromboembolism in Patients with Rheumatoid Arthritis. *Arthritis Care & Research*. Vol. 65, No. 10, October 2013, pp 1600–1607.
- 21 AbbVie. Data on File, ABVRRTI64959.
- 22 AbbVie. Data on File, ABVRRTI66056.
- 23 AbbVie's (ABBV) CEO Richard Gonzalez on Q4 2017 Results - Earnings Call Transcript. Available at: <https://seekingalpha.com/article/4140615-abbvies-abbv-ceo-richard-gonzalez-q4-2017-results-earnings-call-transcript>. Accessed on April 5, 2018.
- 24 HUMIRA [Summary of Product Characteristics]. AbbVie Ltd.; Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000481/WC500050870.pdf. Last updated March 21, 2018. Accessed April 5, 2018.